Plenary Session: Screening, Assessing and Treatment Pregnant … · Plenary Session: Screening,...
Transcript of Plenary Session: Screening, Assessing and Treatment Pregnant … · Plenary Session: Screening,...
![Page 1: Plenary Session: Screening, Assessing and Treatment Pregnant … · Plenary Session: Screening, Assessing and Treatment Pregnant Women with Substance Use Disorders Wednesday, July](https://reader033.fdocuments.net/reader033/viewer/2022053014/5f113ffd864e4d4598034de6/html5/thumbnails/1.jpg)
Plenary Session:Screening, Assessing and Treatment Pregnant Women with Substance Use Disorders
Wednesday, July 10, 2019
9:45 am – 11:00 am
Dr. Mishka Terplan, M.D., Professor, Obstetrics and Gynecology And Psychiatry, Associate Director Of Addiction Medicine, Virginia Commonwealth University
![Page 2: Plenary Session: Screening, Assessing and Treatment Pregnant … · Plenary Session: Screening, Assessing and Treatment Pregnant Women with Substance Use Disorders Wednesday, July](https://reader033.fdocuments.net/reader033/viewer/2022053014/5f113ffd864e4d4598034de6/html5/thumbnails/2.jpg)
Screening, Assessing, and Treating Pregnant Women with Substance Use Disorder
Mishka Terplan MD MPH FACOG DFASAMProfessor Departments OBGYN and Psychiatry
Virginia Commonwealth University
![Page 3: Plenary Session: Screening, Assessing and Treatment Pregnant … · Plenary Session: Screening, Assessing and Treatment Pregnant Women with Substance Use Disorders Wednesday, July](https://reader033.fdocuments.net/reader033/viewer/2022053014/5f113ffd864e4d4598034de6/html5/thumbnails/3.jpg)
Drug Use is Common
Substance Lifetime UseN
Lifetime Use%
IllicitCannabis
131 mil119 mil
49%44%
Tobacco 169 mil 63%
Alcohol 216 mil 80%
Lifetime Drug Use US
![Page 4: Plenary Session: Screening, Assessing and Treatment Pregnant … · Plenary Session: Screening, Assessing and Treatment Pregnant Women with Substance Use Disorders Wednesday, July](https://reader033.fdocuments.net/reader033/viewer/2022053014/5f113ffd864e4d4598034de6/html5/thumbnails/4.jpg)
4
20.1 million people in US (7.5%) with SUDNSDUH 2016 (aged 12 and older)
![Page 5: Plenary Session: Screening, Assessing and Treatment Pregnant … · Plenary Session: Screening, Assessing and Treatment Pregnant Women with Substance Use Disorders Wednesday, July](https://reader033.fdocuments.net/reader033/viewer/2022053014/5f113ffd864e4d4598034de6/html5/thumbnails/5.jpg)
Not everyone who uses drugs becomes addicted
![Page 6: Plenary Session: Screening, Assessing and Treatment Pregnant … · Plenary Session: Screening, Assessing and Treatment Pregnant Women with Substance Use Disorders Wednesday, July](https://reader033.fdocuments.net/reader033/viewer/2022053014/5f113ffd864e4d4598034de6/html5/thumbnails/6.jpg)
What is the risk of opioid addiction among individuals prescribed opioids for pain?
Rates of misuse 12-29% (95%CI:13-38%)Rates of addiction averaged between 8-12% (95% CI: 3-17%)
![Page 7: Plenary Session: Screening, Assessing and Treatment Pregnant … · Plenary Session: Screening, Assessing and Treatment Pregnant Women with Substance Use Disorders Wednesday, July](https://reader033.fdocuments.net/reader033/viewer/2022053014/5f113ffd864e4d4598034de6/html5/thumbnails/7.jpg)
Addiction is not only harm of substance use
![Page 8: Plenary Session: Screening, Assessing and Treatment Pregnant … · Plenary Session: Screening, Assessing and Treatment Pregnant Women with Substance Use Disorders Wednesday, July](https://reader033.fdocuments.net/reader033/viewer/2022053014/5f113ffd864e4d4598034de6/html5/thumbnails/8.jpg)
What happens when women who use drugs become pregnant?
![Page 9: Plenary Session: Screening, Assessing and Treatment Pregnant … · Plenary Session: Screening, Assessing and Treatment Pregnant Women with Substance Use Disorders Wednesday, July](https://reader033.fdocuments.net/reader033/viewer/2022053014/5f113ffd864e4d4598034de6/html5/thumbnails/9.jpg)
0
10
20
30
40
50
60
Alcohol Cigarettes Illicit
What happens when women who use drugs get pregnant?
Not Pregnant First Trimester Second Trimester Third Trimester
National Survey Drug Use and Health 2017 Past Month Use Data, women ages 12-44
![Page 10: Plenary Session: Screening, Assessing and Treatment Pregnant … · Plenary Session: Screening, Assessing and Treatment Pregnant Women with Substance Use Disorders Wednesday, July](https://reader033.fdocuments.net/reader033/viewer/2022053014/5f113ffd864e4d4598034de6/html5/thumbnails/10.jpg)
Those who can’t quit or cut back –likely have a substance use disorder
All pregnant women are motivated to maximize their health and that of their baby-to-be
Continued use in pregnancy is pathognomonic for addiction
![Page 11: Plenary Session: Screening, Assessing and Treatment Pregnant … · Plenary Session: Screening, Assessing and Treatment Pregnant Women with Substance Use Disorders Wednesday, July](https://reader033.fdocuments.net/reader033/viewer/2022053014/5f113ffd864e4d4598034de6/html5/thumbnails/11.jpg)
Addiction: A Brain-Centered Disease Whose Symptoms are Behaviors
Salient Feature: Continued use in spite of adverse consequences
![Page 12: Plenary Session: Screening, Assessing and Treatment Pregnant … · Plenary Session: Screening, Assessing and Treatment Pregnant Women with Substance Use Disorders Wednesday, July](https://reader033.fdocuments.net/reader033/viewer/2022053014/5f113ffd864e4d4598034de6/html5/thumbnails/12.jpg)
The Pregnancy Box
![Page 13: Plenary Session: Screening, Assessing and Treatment Pregnant … · Plenary Session: Screening, Assessing and Treatment Pregnant Women with Substance Use Disorders Wednesday, July](https://reader033.fdocuments.net/reader033/viewer/2022053014/5f113ffd864e4d4598034de6/html5/thumbnails/13.jpg)
Outline
• Assessment (screening and testing)
• Treatment
• The 4th Trimester
• Stigma and Discrimination
![Page 14: Plenary Session: Screening, Assessing and Treatment Pregnant … · Plenary Session: Screening, Assessing and Treatment Pregnant Women with Substance Use Disorders Wednesday, July](https://reader033.fdocuments.net/reader033/viewer/2022053014/5f113ffd864e4d4598034de6/html5/thumbnails/14.jpg)
SAMHSA’s Clinical Guide
https://store.samhsa.gov/product/SMA18-5054
The Clinical Guide consists of 16 factsheets that are organized into 3 sections: Prenatal Care (Factsheets #1–8); Infant Care (Factsheets #9–13); and Maternal Postnatal Care (Factsheets #14–16).
![Page 15: Plenary Session: Screening, Assessing and Treatment Pregnant … · Plenary Session: Screening, Assessing and Treatment Pregnant Women with Substance Use Disorders Wednesday, July](https://reader033.fdocuments.net/reader033/viewer/2022053014/5f113ffd864e4d4598034de6/html5/thumbnails/15.jpg)
1) Assessment: Universal
• Ask permission– “Is it OK if I ask you some questions about smoking, alcohol and other
drugs?”– Patients are usually not offended by questions about substance use if
asked in caring and nonjudgmental manner
• Consider (Validated) Instrument (ACOG recommended)– Alcohol: T-ACE (Sokol 1989); TWEAK (Chang 1999)– Alcohol and other drugs: DAST and MAST (Kemper 1993); 4P’s Plus
(Chasnoff 1999); CRAFFT (Chang 2011) for pregnant adolescents
• Selective screening based on “risk factors” perpetuates discrimination and misses women with addiction
![Page 16: Plenary Session: Screening, Assessing and Treatment Pregnant … · Plenary Session: Screening, Assessing and Treatment Pregnant Women with Substance Use Disorders Wednesday, July](https://reader033.fdocuments.net/reader033/viewer/2022053014/5f113ffd864e4d4598034de6/html5/thumbnails/16.jpg)
![Page 17: Plenary Session: Screening, Assessing and Treatment Pregnant … · Plenary Session: Screening, Assessing and Treatment Pregnant Women with Substance Use Disorders Wednesday, July](https://reader033.fdocuments.net/reader033/viewer/2022053014/5f113ffd864e4d4598034de6/html5/thumbnails/17.jpg)
![Page 18: Plenary Session: Screening, Assessing and Treatment Pregnant … · Plenary Session: Screening, Assessing and Treatment Pregnant Women with Substance Use Disorders Wednesday, July](https://reader033.fdocuments.net/reader033/viewer/2022053014/5f113ffd864e4d4598034de6/html5/thumbnails/18.jpg)
Urine Drug Testing
Screening:Elisa (Point of Care)
Definitive:Gas Chromatography / Mas Spec
![Page 19: Plenary Session: Screening, Assessing and Treatment Pregnant … · Plenary Session: Screening, Assessing and Treatment Pregnant Women with Substance Use Disorders Wednesday, July](https://reader033.fdocuments.net/reader033/viewer/2022053014/5f113ffd864e4d4598034de6/html5/thumbnails/19.jpg)
Point of Care Urine Drug Testing
![Page 20: Plenary Session: Screening, Assessing and Treatment Pregnant … · Plenary Session: Screening, Assessing and Treatment Pregnant Women with Substance Use Disorders Wednesday, July](https://reader033.fdocuments.net/reader033/viewer/2022053014/5f113ffd864e4d4598034de6/html5/thumbnails/20.jpg)
Definitive Testing
https://www.asam.org/resources/guidelines-and-consensus-documents/drug-testing
![Page 21: Plenary Session: Screening, Assessing and Treatment Pregnant … · Plenary Session: Screening, Assessing and Treatment Pregnant Women with Substance Use Disorders Wednesday, July](https://reader033.fdocuments.net/reader033/viewer/2022053014/5f113ffd864e4d4598034de6/html5/thumbnails/21.jpg)
Limits of Urine Testing
http://www.ezkeycup.com/iCup-Drug-Screen-8-p/i-dud-187-013.htm
• It is not a parenting test
• Toxicology tests for
drugs are not sufficient
for a diagnosis of a
substance use disorder
• Having a substance
use disorder is only
one of many other
factors in determining
child safety
• Urine toxicology
screening and
confirmatory testing
• Patient consent
required before
specimen collection
Toxicology screens are not a substitute for verbal, interactive questioning and screening of
patients about their drug and alcohol use.
![Page 22: Plenary Session: Screening, Assessing and Treatment Pregnant … · Plenary Session: Screening, Assessing and Treatment Pregnant Women with Substance Use Disorders Wednesday, July](https://reader033.fdocuments.net/reader033/viewer/2022053014/5f113ffd864e4d4598034de6/html5/thumbnails/22.jpg)
![Page 23: Plenary Session: Screening, Assessing and Treatment Pregnant … · Plenary Session: Screening, Assessing and Treatment Pregnant Women with Substance Use Disorders Wednesday, July](https://reader033.fdocuments.net/reader033/viewer/2022053014/5f113ffd864e4d4598034de6/html5/thumbnails/23.jpg)
![Page 24: Plenary Session: Screening, Assessing and Treatment Pregnant … · Plenary Session: Screening, Assessing and Treatment Pregnant Women with Substance Use Disorders Wednesday, July](https://reader033.fdocuments.net/reader033/viewer/2022053014/5f113ffd864e4d4598034de6/html5/thumbnails/24.jpg)
Number of tests increased 4537% from 2000-2009
![Page 25: Plenary Session: Screening, Assessing and Treatment Pregnant … · Plenary Session: Screening, Assessing and Treatment Pregnant Women with Substance Use Disorders Wednesday, July](https://reader033.fdocuments.net/reader033/viewer/2022053014/5f113ffd864e4d4598034de6/html5/thumbnails/25.jpg)
2011 – 2014: spending on urine tests increased from c $2 to $8.5 billion/year31 Pain Medicine Practices in US received >80% of total income from urine testing
Comprehensive Pain Specialists (54 clinics: largest pain treatment practice in Southeast)2014: Medicare paid CPS at least $11 million for urine tests2015: Medical Director billed $1.8 million
![Page 26: Plenary Session: Screening, Assessing and Treatment Pregnant … · Plenary Session: Screening, Assessing and Treatment Pregnant Women with Substance Use Disorders Wednesday, July](https://reader033.fdocuments.net/reader033/viewer/2022053014/5f113ffd864e4d4598034de6/html5/thumbnails/26.jpg)
![Page 27: Plenary Session: Screening, Assessing and Treatment Pregnant … · Plenary Session: Screening, Assessing and Treatment Pregnant Women with Substance Use Disorders Wednesday, July](https://reader033.fdocuments.net/reader033/viewer/2022053014/5f113ffd864e4d4598034de6/html5/thumbnails/27.jpg)
![Page 28: Plenary Session: Screening, Assessing and Treatment Pregnant … · Plenary Session: Screening, Assessing and Treatment Pregnant Women with Substance Use Disorders Wednesday, July](https://reader033.fdocuments.net/reader033/viewer/2022053014/5f113ffd864e4d4598034de6/html5/thumbnails/28.jpg)
2) Treatment
![Page 29: Plenary Session: Screening, Assessing and Treatment Pregnant … · Plenary Session: Screening, Assessing and Treatment Pregnant Women with Substance Use Disorders Wednesday, July](https://reader033.fdocuments.net/reader033/viewer/2022053014/5f113ffd864e4d4598034de6/html5/thumbnails/29.jpg)
Individuals with the Condition of Addiction Need Treatment
Prenatal Care
Medication
Behavioral Counseling
“Gold Standard” is Integration: Comprehensive co-located service delivery
![Page 30: Plenary Session: Screening, Assessing and Treatment Pregnant … · Plenary Session: Screening, Assessing and Treatment Pregnant Women with Substance Use Disorders Wednesday, July](https://reader033.fdocuments.net/reader033/viewer/2022053014/5f113ffd864e4d4598034de6/html5/thumbnails/30.jpg)
1976
1974
![Page 31: Plenary Session: Screening, Assessing and Treatment Pregnant … · Plenary Session: Screening, Assessing and Treatment Pregnant Women with Substance Use Disorders Wednesday, July](https://reader033.fdocuments.net/reader033/viewer/2022053014/5f113ffd864e4d4598034de6/html5/thumbnails/31.jpg)
No Addiction Treated Addiction Untreated Addiction
Preterm Birth 8.7% 10.1% 19.0%
Low Birthweight 5.5% 7.8% 18.0
Fetal Death 0.4% 0.5% 0.8%
Neonatal Mortality 0.4% 0.4% 1.2%
Post Neonatal Mortality
0.05% 0.03% 0.1%
Treated vs Untreated Addiction
![Page 32: Plenary Session: Screening, Assessing and Treatment Pregnant … · Plenary Session: Screening, Assessing and Treatment Pregnant Women with Substance Use Disorders Wednesday, July](https://reader033.fdocuments.net/reader033/viewer/2022053014/5f113ffd864e4d4598034de6/html5/thumbnails/32.jpg)
How effective is treatment?
0
20
40
60
80
100
Pati
en
ts W
ho
Rela
pse,
%
Similar Relapse (or Noncompliance) Rates
for Drug Dependence Versus Other Chronic Diseases
Drug Addiction1,2Type 1 Diabetes3 Hypertension4 Asthma5
Graph adapted from Caron Foundation. http://www.caron.org/pdfs/RelapseRecovery-2003.pdf., 2. Hoffman NG, Miller NS. Psychiatr Ann.1992;22(8):402-408. 3. Graber AL et al. Diabetes Care. 1992;15(11):1477-1483., 4. Clark LT. Am Heart J. 1991;121(2 pt 2):644-669., 5Dekker FW et al. Eur Respir J. 1993;6(6):886-890.
![Page 33: Plenary Session: Screening, Assessing and Treatment Pregnant … · Plenary Session: Screening, Assessing and Treatment Pregnant Women with Substance Use Disorders Wednesday, July](https://reader033.fdocuments.net/reader033/viewer/2022053014/5f113ffd864e4d4598034de6/html5/thumbnails/33.jpg)
Medications for SUD
Substance Use Disorder Medication
FDA Approved Research Supported
Opioid Use Disorder MethadoneBuprenorphine (+/-naloxone)Naltrexone
Alcohol Use Disorder AcamprosateNaltrexoneDisulfuram
Gabapentin
Nicotine Use Disorder Nicotine Replacement TherapyWellbutrinChantix
![Page 34: Plenary Session: Screening, Assessing and Treatment Pregnant … · Plenary Session: Screening, Assessing and Treatment Pregnant Women with Substance Use Disorders Wednesday, July](https://reader033.fdocuments.net/reader033/viewer/2022053014/5f113ffd864e4d4598034de6/html5/thumbnails/34.jpg)
Addiction: From Reward Seeking to Relief Seeking
![Page 35: Plenary Session: Screening, Assessing and Treatment Pregnant … · Plenary Session: Screening, Assessing and Treatment Pregnant Women with Substance Use Disorders Wednesday, July](https://reader033.fdocuments.net/reader033/viewer/2022053014/5f113ffd864e4d4598034de6/html5/thumbnails/35.jpg)
OUD Treatment: Pharmacotherapy
Maternal
• 70% reduction in overdose related deaths
• Decrease in risk of HIV, HBV, HCV acquisition/transmission
• Increased engagement in prenatal care and recovery treatment
• Treatment is platform for delivery of other services
Fetal
• Reduces fluctuations in maternal opioid levels; reducing fetal stress
• Decrease in intrauterine fetal demise
• Decrease in intrauterine growth restriction
• Decrease in preterm delivery
![Page 36: Plenary Session: Screening, Assessing and Treatment Pregnant … · Plenary Session: Screening, Assessing and Treatment Pregnant Women with Substance Use Disorders Wednesday, July](https://reader033.fdocuments.net/reader033/viewer/2022053014/5f113ffd864e4d4598034de6/html5/thumbnails/36.jpg)
Goal of Pharmacotherapy
• Mu Opioid Receptor Action:
– Decrease or eliminate cravings
– Control physiological withdrawal
– Prevent euphoria from use of other mu agonists
![Page 37: Plenary Session: Screening, Assessing and Treatment Pregnant … · Plenary Session: Screening, Assessing and Treatment Pregnant Women with Substance Use Disorders Wednesday, July](https://reader033.fdocuments.net/reader033/viewer/2022053014/5f113ffd864e4d4598034de6/html5/thumbnails/37.jpg)
Goal of Pharmacotherapy
• Mu Opioid Receptor Action:
– Decrease or eliminate cravings
– Control physiological withdrawal
– Prevent euphoria from use of other mu agonists
• Stability – platform for recovery
• Improved engagement in behavioral care
• Decrease HIV/HCV
• Psychosocial improvement (employment etc)
• Decrease in overdose
![Page 38: Plenary Session: Screening, Assessing and Treatment Pregnant … · Plenary Session: Screening, Assessing and Treatment Pregnant Women with Substance Use Disorders Wednesday, July](https://reader033.fdocuments.net/reader033/viewer/2022053014/5f113ffd864e4d4598034de6/html5/thumbnails/38.jpg)
SAMHSA Clinical Guide Recommendations
• Medically supervised withdrawal is not recommended during pregnancy
• Buprenorphine and methadone are the safest medications for managing OUD during pregnancy
• Transitioning from methadone to buprenorphine or from buprenorphine to methadone during pregnancy is not recommended
![Page 39: Plenary Session: Screening, Assessing and Treatment Pregnant … · Plenary Session: Screening, Assessing and Treatment Pregnant Women with Substance Use Disorders Wednesday, July](https://reader033.fdocuments.net/reader033/viewer/2022053014/5f113ffd864e4d4598034de6/html5/thumbnails/39.jpg)
Methadone and Buprenorphine: Advantages
Methadone Buprenorphine
Advantages
Reduces/eliminates cravings for opioid drugs
Prevents onset of withdrawal for 24 hours
Blocks the effects of other opioids
Promotes increased physical and emotional health
Higher treatment retention than other treatments
Lower risk of overdose
Fewer drug interactions
Office-based treatment delivery
Shorter NAS course
![Page 40: Plenary Session: Screening, Assessing and Treatment Pregnant … · Plenary Session: Screening, Assessing and Treatment Pregnant Women with Substance Use Disorders Wednesday, July](https://reader033.fdocuments.net/reader033/viewer/2022053014/5f113ffd864e4d4598034de6/html5/thumbnails/40.jpg)
Pharmacotherapy
• Pharmacotherapy supported by:– CDC– WHO– SAMHSA– BOP– NCCHC– ACOG– ASAM– AAP– AAFP– Federal Guidelines for Opioid
Treatment 2015(partial list)
• Pharmacotherapy not supported by:
![Page 41: Plenary Session: Screening, Assessing and Treatment Pregnant … · Plenary Session: Screening, Assessing and Treatment Pregnant Women with Substance Use Disorders Wednesday, July](https://reader033.fdocuments.net/reader033/viewer/2022053014/5f113ffd864e4d4598034de6/html5/thumbnails/41.jpg)
SAMHSA’s Guidance: Medically Supervised Withdrawal is Not Recommended
• Pharmacotherapy is the recommended standard of care • Pharmacotherapy helps pregnant women with OUD avoid a return
to substance use, which has the potential for overdose or death
• A decision to withdraw from pharmacotherapy should be made with great care on a case-by-case basis.
• A pregnant woman receiving treatment for OUD may decide to move forward with medically supervised withdrawal if– It can be conducted in a controlled setting– The benefits to her outweigh the risks
Pregnant patients should be advised that withdrawal during pregnancy increases the risk of relapse without fetal or maternal benefit
![Page 42: Plenary Session: Screening, Assessing and Treatment Pregnant … · Plenary Session: Screening, Assessing and Treatment Pregnant Women with Substance Use Disorders Wednesday, July](https://reader033.fdocuments.net/reader033/viewer/2022053014/5f113ffd864e4d4598034de6/html5/thumbnails/42.jpg)
Detoxification:
No increased risk of fetal demise
No difference in NAS
Recurrence more common among those who receive detoxification
Detoxification: Acute Intervention for a Chronic Condition:Clinical Mismatch
![Page 43: Plenary Session: Screening, Assessing and Treatment Pregnant … · Plenary Session: Screening, Assessing and Treatment Pregnant Women with Substance Use Disorders Wednesday, July](https://reader033.fdocuments.net/reader033/viewer/2022053014/5f113ffd864e4d4598034de6/html5/thumbnails/43.jpg)
The Pregnancy Box
![Page 44: Plenary Session: Screening, Assessing and Treatment Pregnant … · Plenary Session: Screening, Assessing and Treatment Pregnant Women with Substance Use Disorders Wednesday, July](https://reader033.fdocuments.net/reader033/viewer/2022053014/5f113ffd864e4d4598034de6/html5/thumbnails/44.jpg)
![Page 45: Plenary Session: Screening, Assessing and Treatment Pregnant … · Plenary Session: Screening, Assessing and Treatment Pregnant Women with Substance Use Disorders Wednesday, July](https://reader033.fdocuments.net/reader033/viewer/2022053014/5f113ffd864e4d4598034de6/html5/thumbnails/45.jpg)
3) The 4th Trimester - Postpartum
• Critical Period– Newborn care, breastfeeding, maternal/infant bonding– Mood changes, sleep disturbances, physiologic changes– Cultural norms, “the ideal mother” in conflict with what it is actually like to
have a newborn– Insurance and welfare realignment
• Neglected Period– Care shifts from frequent to infrequent– From Mom-focused (PNC provider) to Baby-focused (Pediatrician)– From “medical” to “social” (WIC)– Continuity of Care: Addiction Provider
![Page 46: Plenary Session: Screening, Assessing and Treatment Pregnant … · Plenary Session: Screening, Assessing and Treatment Pregnant Women with Substance Use Disorders Wednesday, July](https://reader033.fdocuments.net/reader033/viewer/2022053014/5f113ffd864e4d4598034de6/html5/thumbnails/46.jpg)
The 4th Trimester: Contraception
![Page 47: Plenary Session: Screening, Assessing and Treatment Pregnant … · Plenary Session: Screening, Assessing and Treatment Pregnant Women with Substance Use Disorders Wednesday, July](https://reader033.fdocuments.net/reader033/viewer/2022053014/5f113ffd864e4d4598034de6/html5/thumbnails/47.jpg)
![Page 48: Plenary Session: Screening, Assessing and Treatment Pregnant … · Plenary Session: Screening, Assessing and Treatment Pregnant Women with Substance Use Disorders Wednesday, July](https://reader033.fdocuments.net/reader033/viewer/2022053014/5f113ffd864e4d4598034de6/html5/thumbnails/48.jpg)
https://www.colorado.gov/pacific/sites/default/files/PSD_TitleX3_CFPI-Report.pdf
Colorado LARC Experiment
![Page 49: Plenary Session: Screening, Assessing and Treatment Pregnant … · Plenary Session: Screening, Assessing and Treatment Pregnant Women with Substance Use Disorders Wednesday, July](https://reader033.fdocuments.net/reader033/viewer/2022053014/5f113ffd864e4d4598034de6/html5/thumbnails/49.jpg)
Maternal mortality in the past and its relevance to developing countries today
Am J Clin Nutr. 2000;72(1):241S-246S. doi:10.1093/ajcn/72.1.241S
The 4th Trimester:Maternal Mortality
![Page 50: Plenary Session: Screening, Assessing and Treatment Pregnant … · Plenary Session: Screening, Assessing and Treatment Pregnant Women with Substance Use Disorders Wednesday, July](https://reader033.fdocuments.net/reader033/viewer/2022053014/5f113ffd864e4d4598034de6/html5/thumbnails/50.jpg)
![Page 51: Plenary Session: Screening, Assessing and Treatment Pregnant … · Plenary Session: Screening, Assessing and Treatment Pregnant Women with Substance Use Disorders Wednesday, July](https://reader033.fdocuments.net/reader033/viewer/2022053014/5f113ffd864e4d4598034de6/html5/thumbnails/51.jpg)
![Page 52: Plenary Session: Screening, Assessing and Treatment Pregnant … · Plenary Session: Screening, Assessing and Treatment Pregnant Women with Substance Use Disorders Wednesday, July](https://reader033.fdocuments.net/reader033/viewer/2022053014/5f113ffd864e4d4598034de6/html5/thumbnails/52.jpg)
![Page 53: Plenary Session: Screening, Assessing and Treatment Pregnant … · Plenary Session: Screening, Assessing and Treatment Pregnant Women with Substance Use Disorders Wednesday, July](https://reader033.fdocuments.net/reader033/viewer/2022053014/5f113ffd864e4d4598034de6/html5/thumbnails/53.jpg)
Opioid Crisis: Hepatitis C
![Page 54: Plenary Session: Screening, Assessing and Treatment Pregnant … · Plenary Session: Screening, Assessing and Treatment Pregnant Women with Substance Use Disorders Wednesday, July](https://reader033.fdocuments.net/reader033/viewer/2022053014/5f113ffd864e4d4598034de6/html5/thumbnails/54.jpg)
![Page 55: Plenary Session: Screening, Assessing and Treatment Pregnant … · Plenary Session: Screening, Assessing and Treatment Pregnant Women with Substance Use Disorders Wednesday, July](https://reader033.fdocuments.net/reader033/viewer/2022053014/5f113ffd864e4d4598034de6/html5/thumbnails/55.jpg)
4) It’s more than opioids
![Page 56: Plenary Session: Screening, Assessing and Treatment Pregnant … · Plenary Session: Screening, Assessing and Treatment Pregnant Women with Substance Use Disorders Wednesday, July](https://reader033.fdocuments.net/reader033/viewer/2022053014/5f113ffd864e4d4598034de6/html5/thumbnails/56.jpg)
![Page 57: Plenary Session: Screening, Assessing and Treatment Pregnant … · Plenary Session: Screening, Assessing and Treatment Pregnant Women with Substance Use Disorders Wednesday, July](https://reader033.fdocuments.net/reader033/viewer/2022053014/5f113ffd864e4d4598034de6/html5/thumbnails/57.jpg)
Our response to the opioid crisis must not be opioid-exclusive
![Page 58: Plenary Session: Screening, Assessing and Treatment Pregnant … · Plenary Session: Screening, Assessing and Treatment Pregnant Women with Substance Use Disorders Wednesday, July](https://reader033.fdocuments.net/reader033/viewer/2022053014/5f113ffd864e4d4598034de6/html5/thumbnails/58.jpg)
FETAL ALCOHOL SPECTRUM DISORDERS (FASDS)
AS IDENTIFIED BY
THE NATIONAL ORGANIZATION ON FETAL ALCOHOL SYNDROME (NOFAS)
“……..an umbrella term describing the range of effects that can occur in an individual who is exposed to alcohol during the nine month prenatal period before birth. These effects may include physical, mental, behavioral, and/or learning disabilities with possible lifelong implications. The term FASD is not intended for use as a clinical diagnosis.”
Diagnostic terms under the FASDs umbrella include:
▪ Fetal Alcohol Syndrome (FAS)
▪ Partial Fetal Alcohol Syndrome (pFAS)
▪ Neurobehavioral Disorder Associated with Prenatal Alcohol Exposure (ND-PAE)
▪ Alcohol Related Neurodevelopmental Disorder (ARND)
▪ Alcohol Related Birth Defects (ARBD)
https://www.nofas.org/about-fasd/
![Page 59: Plenary Session: Screening, Assessing and Treatment Pregnant … · Plenary Session: Screening, Assessing and Treatment Pregnant Women with Substance Use Disorders Wednesday, July](https://reader033.fdocuments.net/reader033/viewer/2022053014/5f113ffd864e4d4598034de6/html5/thumbnails/59.jpg)
Opioid Use During Pregnancy Alcohol Use During Pregnancy
Prevalence of use 1.6%-8.5% of pregnant women
use opioids; however, it’s on the
rise1
Approximately 8.5% of pregnant women
drink alcohol at some point during
pregnancy1
Likelihood of
developing
NAS is seen in 30-80% of infants
born to women who used
opioids in the third trimester2
2-5% of school age children may have FASDs3
Negative
effects/Disabilities
Neonatal Abstinence Syndrome
(NAS) 4
Fetal Alcohol Spectrum Disorders (FASDs)1
Duration of effects Unknown4 FASDs last a lifetime 5
COMPARING AND CONTRASTING ALCOHOL USE AND OPIOID USE
DURING PREGNANCY
![Page 60: Plenary Session: Screening, Assessing and Treatment Pregnant … · Plenary Session: Screening, Assessing and Treatment Pregnant Women with Substance Use Disorders Wednesday, July](https://reader033.fdocuments.net/reader033/viewer/2022053014/5f113ffd864e4d4598034de6/html5/thumbnails/60.jpg)
Comparing and Contrasting Alcohol use and Opioid use During
Pregnancy (Continued)
Opioid Use During Pregnancy Alcohol Use During Pregnancy
Cost of Care Average of $90,000 per case of NAS6 Estimate $1.2-2.5 million per case of
FAS7
Screening and Brief
Intervention
Universal screening using the 5 P’s
tool, and brief intervention8
Universal screening using the AUDIT (US)
tool, and brief intervention9
Ethics Avoid separation of mother and
child10
Avoid separation of mother and child 10
Treatment Medication-assisted therapy (MAT)2 Appropriate treatment referral for
alcohol use disorder **See treatment resource directories on ACOG website: https://www.acog.org/About-ACOG/ACOG-Departments/Tobacco--Alcohol--and-Substance-Abuse/Fetal-Alcohol-Spectrum-Disorders-Prevention-Program/Provider-Resources/FASD-Resource-Directory
![Page 61: Plenary Session: Screening, Assessing and Treatment Pregnant … · Plenary Session: Screening, Assessing and Treatment Pregnant Women with Substance Use Disorders Wednesday, July](https://reader033.fdocuments.net/reader033/viewer/2022053014/5f113ffd864e4d4598034de6/html5/thumbnails/61.jpg)
Conclusion
• Assessment for Substance Use should be universal in PNC
• Urine Drug Testing: poor test characteristics, poorly interpreted, lead to patient discharge from practice (in pain clinics)
• Treatment Works – women with treated SUD have birth outcomes similar to general population
• Need to continue attention past delivery: the 4th Trimester
• Public Health demands a broad response to opioid crisis